Halozyme Therapeutics | HALO - Capital Ordinário

Preço das Ações
63.43
Mudança Diária
0.16 0.25%
Mensal
-10.21%
Anual
-2.66%
Q1 Previsão
61.53




Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.81M 13K 2025-12
Amgen USD 539M 1000K 2025-12
Baxter International USD 514.28M 168.72M 2025-12
Cara Therapeutics USD 2K 3K 2025-03
Cytokinetics USD 122.26M 145K 2025-12
DBV Technologies USD 136.82M 51.98K 2025-09
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
MannKind USD 307.83M 806K 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 19K 0 2024-09
Pfizer USD 5.69B 1000K 2025-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
United Therapeutics USD 43.64M 740K 2025-12
Vanda Pharmaceuticals USD 58K 0 2024-12